Cancers 2013, 5(4), 1676-1690; doi:10.3390/cancers5041676
Review

Circulating Tumor Cells in Prostate Cancer

1email, 2email and 3,* email
Received: 25 September 2013; in revised form: 20 November 2013 / Accepted: 25 November 2013 / Published: 4 December 2013
(This article belongs to the Special Issue Circulating Tumor Cells in Cancers)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Circulating tumor cells (CTCs) can provide a non-invasive, repeatable snapshot of an individual patient’s tumor. In prostate cancer, CTC enumeration has been extensively studied and validated as a prognostic tool and has received FDA clearance for use in monitoring advanced disease. More recently, CTC analysis has been shifting from enumeration to more sophisticated molecular characterization of captured cells, which serve as a “liquid biopsy” of the tumor, reflecting molecular changes in an individual’s malignancy over time. Here we will review the main CTC studies in advanced and localized prostate cancer, highlighting the important gains as well as the challenges posed by various approaches, and their implications for advancing prostate cancer management.
Keywords: circulating tumor cell; prostate cancer; personalized medicine
PDF Full-text Download PDF Full-Text [589 KB, Updated Version, uploaded 9 December 2013 14:28 CET]
The original version is still available [589 KB, uploaded 4 December 2013 13:46 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Hu, B.; Rochefort, H.; Goldkorn, A. Circulating Tumor Cells in Prostate Cancer. Cancers 2013, 5, 1676-1690.

AMA Style

Hu B, Rochefort H, Goldkorn A. Circulating Tumor Cells in Prostate Cancer. Cancers. 2013; 5(4):1676-1690.

Chicago/Turabian Style

Hu, Brian; Rochefort, Holly; Goldkorn, Amir. 2013. "Circulating Tumor Cells in Prostate Cancer." Cancers 5, no. 4: 1676-1690.

Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert